The results of a new colon cancer study are being called “unprecedented” and “unheard-of.”
Now, everyone is looking to GlaxoSmithKline drug called Dostarlimab.
How effective is the drug?
A small cancer trial led by a doctor in New York City has reportedly achieved total cancer remission in all of the patients. The trial was led by doctors at Memorial Sloan Kettering and backed by drug-maker GlaxoSmithKline. The trial treated twelve patients– all who have a rare mutation of a specific cancer in the early stages.
All 12 patients had rectal cancer that had not spread beyond the local area. Each patients tumors all had a mutation that impacted the cells’ ability to repair damage to DNA.
Now, all 12 patients are in complete remission without surgery, chemotherapy, and no severe adverse side effects. This success has been attributed to the trial drug Dostarlimab.
Although these results seem promising, the trial needs to be replicated and expanded. It is unclear if Dostarlimab will have uses beyond this specific application.
Who makes Dostarlimab?
The drug Dostarlimab was developed by Tesaro. Tesaro is Massachusetts-based biotech company that became a part of GlaxoSmithKline in 2019. It is also known as the brand name Jemparli.
Dostarlimab is a monoclonal antibody. It was first approved for cancer treatment in 2021.